Literature DB >> 33507309

High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019.

Werner J D Ouwendijk1, Matthijs P Raadsen1, Jeroen J A van Kampen1, Robert M Verdijk2, Jan H von der Thusen2, Lihui Guo3,4, Rogier A S Hoek5, Johannes P C van den Akker6, Henrik Endeman6, Thomas Langerak1, Richard Molenkamp1, Diederik Gommers6, Marion P G Koopmans1, Eric C M van Gorp1, Georges M G M Verjans1, Bart L Haagmans1.   

Abstract

Lower respiratory tract (LRT) disease induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can deteriorate to acute respiratory distress syndrome (ARDS). Because the release of neutrophil extracellular traps (NETs) is implicated in ARDS pathogenesis, we investigated the presence of NETs and correlates of pathogenesis in blood and LRT samples of critically ill patients with COVID-19. Plasma NET levels peaked early after intensive care unit admission and were correlated with the SARS-CoV-2 RNA load in sputum and levels of neutrophil-recruiting chemokines and inflammatory markers in plasma samples. The baseline plasma NET quantity was correlated with disease severity but was not associated with soluble markers of thrombosis or with development of thrombosis. High NET levels were present in LRT samples and persisted during the course of COVID-19, consistent with the detection of NETs in bronchi and alveolar spaces in lung tissue from deceased patient with COVID-19. Thus, NETs are produced and retained in the LRT of critically ill patients with COVID-19 and could contribute to SARS-CoV-2-induced ARDS disease.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; acute respiratory distress syndrome; neutrophil extracellular traps; neutrophils

Year:  2021        PMID: 33507309      PMCID: PMC7928833          DOI: 10.1093/infdis/jiab050

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  SARS-CoV-2 pathogenesis.

Authors:  Mart M Lamers; Bart L Haagmans
Journal:  Nat Rev Microbiol       Date:  2022-03-30       Impact factor: 60.633

Review 2.  Mechanistic Understanding of Lung Inflammation: Recent Advances and Emerging Techniques.

Authors:  Chrysi Keskinidou; Alice G Vassiliou; Ioanna Dimopoulou; Anastasia Kotanidou; Stylianos E Orfanos
Journal:  J Inflamm Res       Date:  2022-06-15

Review 3.  Neutrophils in COVID-19: Not Innocent Bystanders.

Authors:  Ellen McKenna; Richard Wubben; Johana M Isaza-Correa; Ashanty M Melo; Aisling Ui Mhaonaigh; Niall Conlon; James S O'Donnell; Clíona Ní Cheallaigh; Tim Hurley; Nigel J Stevenson; Mark A Little; Eleanor J Molloy
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

4.  ICODE: the international COVID-19 thrombosis biomarkers colloquium-novel soluble biomarkers: circulating cell-free nucleic acids and other molecules.

Authors:  Krystin Krauel; Daniel Duerschmied
Journal:  J Thromb Thrombolysis       Date:  2021-05-12       Impact factor: 2.300

5.  Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin.

Authors:  Rebecca Dowey; Joby Cole; A A Roger Thompson; Rebecca C Hull; Chenghao Huang; Jacob Whatmore; Ahmed Iqbal; Kirsty L Bradley; Joanne McKenzie; Allan Lawrie; Alison M Condliffe; Endre Kiss-Toth; Ian Sabroe; Lynne R Prince
Journal:  ERJ Open Res       Date:  2022-04-04

6.  Comparative Transcriptomic and Molecular Pathway Analyses of HL-CZ Human Pro-Monocytic Cells Expressing SARS-CoV-2 Spike S1, S2, NP, NSP15 and NSP16 Genes.

Authors:  Anshika Sharma; Joe W Ong; Mun Fai Loke; Eng Guan Chua; Joseph J Lee; Hyung Won Choi; Yee Joo Tan; Sunil K Lal; Vincent T Chow
Journal:  Microorganisms       Date:  2021-05-31

Review 7.  Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.

Authors:  Jon Hazeldine; Janet M Lord
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 8.  Patients with COVID-19: in the dark-NETs of neutrophils.

Authors:  Maximilian Ackermann; Hans-Joachim Anders; Rostyslav Bilyy; Gary L Bowlin; Christoph Daniel; Rebecca De Lorenzo; Mikala Egeblad; Timo Henneck; Andrés Hidalgo; Markus Hoffmann; Bettina Hohberger; Yogendra Kanthi; Mariana J Kaplan; Jason S Knight; Jasmin Knopf; Elzbieta Kolaczkowska; Paul Kubes; Moritz Leppkes; Aparna Mahajan; Angelo A Manfredi; Christian Maueröder; Norma Maugeri; Ioannis Mitroulis; Luis E Muñoz; Teluguakula Narasaraju; Elisabeth Naschberger; Indira Neeli; Lai Guan Ng; Marko Z Radic; Konstantinos Ritis; Patrizia Rovere-Querini; Mirco Schapher; Christine Schauer; Hans-Uwe Simon; Jeeshan Singh; Panagiotis Skendros; Konstantin Stark; Michael Stürzl; Johan van der Vlag; Peter Vandenabeele; Ljubomir Vitkov; Maren von Köckritz-Blickwede; Cansu Yanginlar; Shida Yousefi; Alexander Zarbock; Georg Schett; Martin Herrmann
Journal:  Cell Death Differ       Date:  2021-05-24       Impact factor: 15.828

Review 9.  Role of Neutrophil Extracellular Traps in COVID-19 Progression: An Insight for Effective Treatment.

Authors:  María Amparo Blanch-Ruiz; Raquel Ortega-Luna; Guillermo Gómez-García; Maria Ángeles Martínez-Cuesta; Ángeles Álvarez
Journal:  Biomedicines       Date:  2021-12-23

Review 10.  PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis.

Authors:  Willie Elliott; Maheedhara R Guda; Swapna Asuthkar; Narasaraju Teluguakula; Durbaka V R Prasad; Andrew J Tsung; Kiran K Velpula
Journal:  Biomedicines       Date:  2021-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.